MAPT and amyotrophic lateral sclerosis: Dual orexin receptor antagonists, such as suvorexant, have shown promise in reducing amyloid‐β and tau accumulation in Alzheimer's disease, as well as ameliorating sleep alterations in Huntington's and ALS models.